AP3M2 and rectal cancer: Conversely, no significant association between AP3M2 expression and drug response was observed among rectal cancer patients treated with oxaliplatin (AUC = 0.580, p-value = 0.230), 5-fluorouracil (AUC = 0.509, p-value = 0.440), or Irinotecan (AUC = 0.643, p-value = 280) (Fig. 4).